Psychiatric Disorders During Pregnancy

Lee S. Cohen, MD
Director, Ammon-Pinizzotto Center for Women’s Mental Health
Massachusetts General Hospital
Edmund and Carroll Carpenter Professor of Psychiatry
Harvard Medical School
Disclosures

My spouse/partner and I have the following relevant financial relationship with a commercial interest to disclose:

**12-Month Disclosure**

**Research Support for the National Pregnancy Registry for Atypical Antipsychotics:** Alkermes Biopharmaceuticals; Aurobindo Pharma; Auromedics Pharma LLC; Janssen Pharmaceutica; Otsuka Pharmaceuticals; Teva Pharmaceuticals; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc; Supernus Pharmaceuticals

**Other research support:** Brain & Behavior Research Foundation; National Institute on Aging; National Institutes of Health; SAGE Therapeutics

**Advisory/Consulting:** Alkermes Biopharmaceuticals, JDS Therapeutics LLC; As an employee of MGH, Dr. Cohen works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies, including Alkermes Biopharmaceuticals and Praxis Precision Medicines, Inc.

**Honoraria:** None

**Royalty/patent, other income:** None
Reproductive Psychiatry and the COVID-19 Pandemic

- Family planning and the pandemic
- Telemedicine and implications for pregnancy and postpartum period
- Infertility treatment and the pandemic
- Perinatal anxiety during the COVID 19 crisis
- Importance of euthymia during pregnancy
- Reframing postpartum experience

Virtual Rounds at CWMH during COVID: Wednesdays at 2 PM – Community in Reproductive Psychiatry

Resource: Join us for Virtual Rounds at the Center for Women’s Mental Health on Wednesdays

By MGH Center for Women’s Mental Health | April 3rd, 2020 | Resources | 0 Comments

As our faculty at the Center for Women’s Mental Health (CWMH) have gone fully remote with respect to clinical and research activity, we have managed to stay connected these last three weeks with “virtual rounds”. For over 25 years, our group has met on Wednesdays at midday to discuss clinical cases we have seen across the week and also to discuss recently published papers in reproductive psychiatry. We look forward to Wednesdays as we get to talk about how we think about treatment options with respect to presented cases and the decisions patients make about treatment before, during, and after pregnancy. Particular attention is given to the safest use of psychiatric medications during pregnancy, the postpartum period and lactation. Three decades after founding the Center, I still love Wednesday rounds and always learn something by listening to cases and hearing how my colleagues think about perinatal psychiatric disorders. We are continuing to round during the COVID19 epidemic and Zoom proves to be the next best thing to being there.

https://womensmentalhealth.org/posts/resource-join-us-for-virtual-rounds-at-the-center-for-womens-mental-health-on-wednesdays/
Treatment considerations for women with MDD in pregnancy and the postpartum period : Take Homes

- Depression during pregnancy is strongest predictor of postpartum depression
- **Nothing is more important maternal euthymia**
- There are abundant data derived from multiple sources supporting safety of many psychiatric medications used during pregnancy with some particular exceptions (valproate)
- Impact of untreated depression and stress during pregnancy will continue to be increasingly appreciated as a toxic exposure with respect to obstetrical outcome and longer term neurodevelopmental outcomes
Are pregnant women protected against relapse or new onset of major depression?

To maintain or to discontinue antidepressant?

Evans et al. *BMJ.* 2001
Yonkers et al. *Epidemiology* 2011
Roca et al. *J Affective Disorders* 2013
Bayrampour et al. *J Clin Psychiatry* 2020
Time to Relapse in Patients Who Maintained or Discontinued Antidepressant


Gestational Age

Percentage of Patients Remaining Well

Maintained (N = 82)

Discontinued (N = 65)
Women's Mental Health Across the Life Cycle
Psychotropic Drug Use in Pregnancy

- Medications used when risk to mother and fetus from disorder outweighs risks of pharmacotherapy
- Optimum risk/benefit decision for psychiatrically ill pregnant women
- Patients with similar illness histories make different decisions regarding treatment during pregnancy
- No decision is risk-free
- Collaborative, patient-centered approach required

Henshaw Fam Plann Perspect. 1998
Treatment of Depression During Pregnancy: Lessons Learned and New Directions

- Focus of concern regarding known and unknown risks of fetal exposure to psychiatric medications is increasingly balanced by data supporting risk of exposure to *disorder, stress and HPA-axis dysregulation on fetoplacental unit*

- Enhanced appreciation for impact of disorder and chronic stress on long term behavioral outcomes
Stimulates Labor
Increases Risk for Preterm Birth

Dysregulation of the HPA Axis

Elevated CRH

Elevated Cortisol Levels

Stimulates Labor
Increases Risk for Preterm Birth
Decreases Placental Blood Flow
Decreases Birth Weight

IN UTERO

Programming of Fetal HPA Axis
Dysregulation of HPA Axis
Increased Reactivity to Stress
Increased Vulnerability to Mood and Anxiety Disorders

Implications of impact of stress associated with pandemic on long-term neurodevelopmental outcomes
Original Investigation | META-ANALYSIS

Neonatal Outcomes in Women With Untreated Antenatal Depression Compared With Women Without Depression: A Systematic Review and Meta-analysis

Alexander Jarde, PhD; Michelle Morais, MD; Dawn Kingston, PhD; Rebecca Giallo, PhD; Glenda M. MacQueen, MD; Lucy Giglia, MD; Joseph Beyene, PhD; Yi Wang, BHSc; Sarah D. McDonald, MD

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2016.0934
Published online June 8, 2016.
What is the Safest Antidepressant for Women of Childbearing Age?
FDA Pregnancy Categories – History

• **Category A:**
  - Well controlled studies in human pregnancy show no increased risk to the fetus

• **Category B:**
  - Animal studies show no increased risk to the fetus  OR
  - Animal studies show an increased risk to the fetus but well controlled human studies do not.

• **Category C:**
  - Animal studies show an increased risk to the fetus and there are no well controlled studies in human pregnancy  OR
  - There aren’t any animal studies or well controlled human studies.
FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products

For Immediate Release  December 3, 2014

The U.S. Food and Drug Administration published a final rule today that sets standards for how information about using medicines during pregnancy and breastfeeding is presented in the labeling of prescription drug and biological products.
SSRI Use During Pregnancy

• Recent findings and more data inform the pharmacologic treatment of depression during pregnancy
  – Consistent conclusions that the absolute risk of SSRI exposure in pregnancy is small\(^1-3\)
  – Consistent pattern of malformations with SSRI exposure is lacking
  – Case-control studies reveal inconsistent data regarding teratogenic risk of individual SSRIs\(^4-9\)

Reproductive safety data on SSRIs exceed what is known about most other medicines used in pregnancy

---

Antidepressant Use in Pregnancy and the Risk of Cardiac Defects

Krista F. Huybrechts, Ph.D., Kristin Palmsten, Sc.D., Jerry Avorn, M.D., Lee S. Cohen, M.D., Lewis B. Holmes, M.D., Jessica M. Franklin, Ph.D., Helen Mogun, M.S., Raisa Levin, M.S., Mary Kowal, B.A., Soko Setoguchi, M.D., Dr.P.H., and Sonia Hernández-Díaz, M.D., Dr.P.H.

- No evidence of increased risk for major malformations or cardiovascular malformations in children of pregnant women exposed to SSRIs
Cardiovascular Malformation and Fetal SSRI Exposure

Huybrechts et al. *NEJM* 2014.

<table>
<thead>
<tr>
<th>Exposure Group According to Outcome</th>
<th>Unadjusted Analysis</th>
<th>Depression-Restricted Analysis</th>
<th>Depression-Restricted Analysis with Propensity-Score Stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Right ventricular outflow tract obstruction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any antidepressant</td>
<td>1.11 (0.89–1.38)</td>
<td>1.02 (0.78–1.34)</td>
<td>0.92 (0.67–1.25)</td>
</tr>
<tr>
<td>SSRI</td>
<td>1.12 (0.87–1.45)</td>
<td>1.06 (0.79–1.42)</td>
<td>0.99 (0.70–1.43)</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>1.22 (0.74–2.00)</td>
<td>1.09 (0.62–1.90)</td>
<td>1.07 (0.59–1.93)</td>
</tr>
<tr>
<td>Sertaline</td>
<td>1.03 (0.64–1.66)</td>
<td>1.13 (0.69–1.84)</td>
<td>1.12 (0.67–1.88)</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>1.23 (0.75–2.02)</td>
<td>1.02 (0.57–1.81)</td>
<td>0.93 (0.50–1.72)</td>
</tr>
<tr>
<td>Tricyclic antidepressant</td>
<td>1.14 (0.57–2.28)</td>
<td>1.10 (0.46–2.68)</td>
<td>0.94 (0.37–2.26)</td>
</tr>
<tr>
<td>SNRI</td>
<td>1.47 (0.83–2.66)</td>
<td>1.47 (0.82–2.62)</td>
<td>1.06 (0.55–2.05)</td>
</tr>
<tr>
<td>Bupropion</td>
<td>1.05 (0.58–1.92)</td>
<td>1.10 (0.58–2.06)</td>
<td>1.09 (0.56–2.10)</td>
</tr>
<tr>
<td>Other</td>
<td>0.96 (0.48–1.93)</td>
<td>0.61 (0.25–1.47)</td>
<td>0.61 (0.24–1.52)</td>
</tr>
<tr>
<td><strong>Ventricular septal defect</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any antidepressant</td>
<td>1.23 (1.09–1.28)</td>
<td>1.02 (0.88–1.19)</td>
<td>0.95 (0.79–1.14)</td>
</tr>
<tr>
<td>SSRI</td>
<td>1.20 (1.04–1.39)</td>
<td>1.01 (0.86–1.22)</td>
<td>0.98 (0.81–1.26)</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>1.09 (0.81–1.47)</td>
<td>0.77 (0.53–1.12)</td>
<td>0.73 (0.49–1.09)</td>
</tr>
<tr>
<td>Sertaline</td>
<td>1.24 (0.96–1.59)</td>
<td>1.09 (0.82–1.45)</td>
<td>1.04 (0.76–1.41)</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>1.20 (0.99–1.59)</td>
<td>1.14 (0.83–1.56)</td>
<td>1.12 (0.80–1.57)</td>
</tr>
<tr>
<td>Tricyclic antidepressant</td>
<td>1.11 (0.74–1.66)</td>
<td>1.08 (0.65–1.81)</td>
<td>0.86 (0.50–1.47)</td>
</tr>
<tr>
<td>SNRI</td>
<td>1.56 (1.14–2.14)</td>
<td>1.36 (0.97–1.92)</td>
<td>1.24 (0.85–1.82)</td>
</tr>
<tr>
<td>Bupropion</td>
<td>1.22 (0.89–1.67)</td>
<td>0.93 (0.63–1.38)</td>
<td>0.88 (0.58–1.34)</td>
</tr>
<tr>
<td>Other</td>
<td>1.21 (0.85–1.73)</td>
<td>1.04 (0.70–1.53)</td>
<td>0.99 (0.64–1.53)</td>
</tr>
<tr>
<td><strong>Other cardiac defect</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any antidepressant</td>
<td>1.35 (1.21–1.52)</td>
<td>1.27 (1.10–1.47)</td>
<td>1.15 (0.97–1.36)</td>
</tr>
<tr>
<td>SSRI</td>
<td>1.34 (1.17–1.54)</td>
<td>1.25 (1.07–1.47)</td>
<td>1.19 (0.99–1.43)</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>1.18 (0.89–1.57)</td>
<td>1.11 (0.81–1.53)</td>
<td>1.10 (0.78–1.55)</td>
</tr>
<tr>
<td>Sertaline</td>
<td>1.39 (1.20–1.76)</td>
<td>1.25 (0.96–1.64)</td>
<td>1.10 (0.89–1.95)</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>1.37 (1.05–1.79)</td>
<td>1.26 (0.98–1.61)</td>
<td>1.23 (0.89–1.70)</td>
</tr>
<tr>
<td>Tricyclic antidepressant</td>
<td>0.83 (0.52–1.32)</td>
<td>0.55 (0.35–0.85)</td>
<td>0.79 (0.45–1.40)</td>
</tr>
<tr>
<td>SNRI</td>
<td>1.51 (1.10–2.08)</td>
<td>1.50 (1.08–2.09)</td>
<td>1.31 (0.90–1.90)</td>
</tr>
<tr>
<td>Bupropion</td>
<td>2.52 (1.14–2.92)</td>
<td>1.34 (0.97–1.87)</td>
<td>1.16 (0.81–1.67)</td>
</tr>
<tr>
<td>Other</td>
<td>1.79 (1.34–2.40)</td>
<td>1.61 (1.17–2.22)</td>
<td>1.65 (1.15–2.37)</td>
</tr>
</tbody>
</table>
“Poor Neonatal Adaptation” and SSRI Use During Pregnancy

• **Consistent data:** Late trimester exposure to SSRIs is associated with *transient* irritability, agitation, jitteriness, and tachypnea (25-30%)

• Overall studies do not adequately control for maternal mental health condition, adequate blinding of exposure in neonatal assessments

• **Clinical implication:** Should women be treated with antidepressants late in pregnancy and during labor and delivery (Warburton et al. 2010)

• Are any subgroups of newborns vulnerable to enduring symptoms beyond the first days of life?

Chambers, *BMJ,* 2009
What are the Long-term Neurobehavioral Effects of Prenatal Exposure to an Antidepressant?
Neurodevelopmental Outcomes in Kindergartners with Prenatal Exposure to Antidepressants

By MGH Center for Women's Mental Health | June 2nd, 2020 | Antidepressants and Pregnancy, Child Development, Psychiatric Disorders During Pregnancy | 0 Comments

While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital malformations, and we have less information on longer term neurodevelopmental outcomes. In a recent study, Singal and colleagues look at neurodevelopmental outcomes in kindergartners with prenatal exposure to

Full blog post: [https://womensmentalhealth.org/posts/antidepressants-neurodevelopment/](https://womensmentalhealth.org/posts/antidepressants-neurodevelopment/)


Research

JAMA Pediatrics | Original Investigation

Risk for Autism Spectrum Disorders According to Period of Prenatal Antidepressant Exposure
A Systematic Review and Meta-analysis

Antonia Mezzacappa, MD; Pierre-Alexandre Lasica; Francesco Gianfagna, MD, PhD; Odile Cazas, MD; Patrick Hardy, MD, PhD; Bruno Falissard, MD, PhD; Anne-Laure Sutter-Dallay, MD, PhD; Florence Gressier, MD, PhD

Published online April 17, 2017.
Antidepressant Exposure During Pregnancy and Risk of Autism in the Offspring, 1:
Meta-Review of Meta-Analyses

Chittaranjan Andrade, MD

Table 1. Important Findings From the Meta-Analysis of Kobayashi et al9

1. SSR1 exposure during pregnancy was associated with an increased risk of ASD in the offspring in the case-control studies (5 studies; OR = 1.37; 95% CI, 1.08–1.74) and in one (2 studies; OR = 1.89; 95% CI, 1.28–1.88) but not the other (2 studies; OR = 1.69; 95% CI, 0.80–3.57) combination of the cohort studies.

2. There was no difference in ASD risk when exposure was compared between SSRIs and other antidepressant drugs in either case-control or cohort study analyses.

3. When analysis was restricted to datasets of mothers with psychiatric disorders, SSRIs were not associated with an increased risk of ASD in the case-control studies (1 study; OR = 1.86; 95% CI, 0.76–4.58) and in both sets of cohort studies (2 studies, each; OR = 0.79; 95% CI, 0.51–1.23 and OR = 1.03; 95% CI, 0.49–2.15).

Abbreviations: ASD = autism spectrum disorder, CI = confidence interval, OR = odds ratio, SSR1 = selective serotonin reuptake inhibitor.

Kobayashi et al9

1. SSR1 exposure during pregnancy was associated with an increased risk of ASD in the offspring in the case-control studies (5 studies; OR = 1.37; 95% CI, 1.08–1.74) and in one (2 studies; OR = 1.89; 95% CI, 1.28–1.88) but not the other (2 studies; OR = 1.69; 95% CI, 0.80–3.57) combination of the cohort studies.

2. There was no difference in ASD risk when exposure was compared between SSRIs and other antidepressant drugs in either case-control or cohort study analyses.

3. When analysis was restricted to datasets of mothers with psychiatric disorders, SSRIs were not associated with an increased risk of ASD in the case-control studies (1 study; OR = 1.86; 95% CI, 0.76–4.58) and in both sets of cohort studies (2 studies, each; OR = 0.79; 95% CI, 0.51–1.23 and OR = 1.03; 95% CI, 0.49–2.15).

Abbreviations: ASD = autism spectrum disorder, CI = confidence interval, OR = odds ratio, SSR1 = selective serotonin reuptake inhibitor.

Table 3. Important Findings From the Meta-Analysis of Brown et al11

1. In unadjusted analyses, exposure to SSR1s during pregnancy was associated with an increased risk of ASD in the offspring in both case-control (4 studies; OR = 1.7; 95% CI, 1.3–2.3) and cohort (2 studies; OR = 1.8; 95% CI, 1.3–2.6) studies.

2. In unadjusted analyses, exposure to SSR1s during the first trimester was associated with an increased risk of ASD in the offspring in both case-control (4 studies; OR = 2.0; 95% CI, 1.3–3.1) and cohort (2 studies; OR = 1.8; 95% CI, 1.3–2.6) studies.

3. After adjusting for potential confounders, exposure to SSR1s during pregnancy was associated with borderline significant risk of ASD in the offspring in the case-control studies (4 studies, OR = 1.4; 95% CI, 1.0–2.0) and with nonsignificant risk in the cohort studies (2 studies; OR = 1.5; 95% CI, 0.9–2.7).

4. After adjusting for potential confounders, exposure to SSR1s during the first trimester was associated with increased risk of ASD in the offspring in the case-control studies (4 studies, OR = 1.7; 95% CI, 1.1–2.6) and with nonsignificant risk in the cohort studies (1 study; OR = 1.4; 95% CI, 1.0–1.9).

5. In analyses restricted to datasets that controlled for maternal mental illness, SSR1 exposure during pregnancy was not associated with an increased risk of ASD in the offspring in either case-control (3 studies; OR = 1.4; 95% CI, 0.9–2.2) or cohort (2 studies; OR = 1.5; 95% CI, 0.9–2.7) studies.

6. In analyses restricted to datasets that controlled for maternal mental illness, SSR1 exposure during the first trimester was associated with an increased risk of ASD in the offspring in the case-control studies (3 studies; OR = 1.8; 95% CI, 1.1–3.1). In the cohort studies, the risk was not significant (1 study; OR = 1.4; 95% CI, 1.0–1.9).

Abbreviations: ASD = autism spectrum disorder, CI = confidence interval, OR = odds ratio, SSR1 = selective serotonin reuptake inhibitor.
Treatment Guidelines Depression: Does Severity Drive Treatment Recommendations (and Patient Choice)

- **Psychotherapy: First-line for mild to moderate MDD**
- **Lifestyle components: Nutrition, weight management, prenatal care; treatment for co-morbid substance abuse**
- **Evidence base for CBT, Behavioral Activation and MBCT (prevention)**
- **Women trying to conceive who have histories of MDD:**
  - Encourage period of euthymia
  - Sustained remission: consider tapering and discontinuing?
  - More recently depressed or with symptoms: consider remaining on medication, optimizing medication
- **Pregnant women with severe MDD: Medication is first-line**
- **Pregnant women on antidepressants during pregnancy:** take into account patient preferences, previous course of illness
- **Medication selection should be based on known safety information**

MDD, major depressive disorder.
Treatment of Depression During Pregnancy: Lessons Learned

• Treatment decisions are complex (maternal and fetal benefits and risks)
• Absolute quantification of risk associated with fetal exposure to medication or maternal disease is impossible
• No treatment decision is “perfect”
• Each treatment decision should try to optimize pregnancy outcomes for the mother and her child
• Consider the risks of untreated disease and the risks of medication treatment
• Wisdom of changing or discontinuing AD proximate to delivery is sparse

Kallen Obstet Gynecol Int. 2012
Palmsten and Hernandez-Diaz Epidemiology 2012
Bipolar Disorder During Pregnancy
Relapse of Bipolar Disorder During Pregnancy

Pharmacologic Treatment of Pregnant Women with Bipolar Disorder: Weighing Imperfect Options

• Commonly employed antimanic agents are either known teratogens or have incomplete reproductive safety data
• Risks of untreated bipolar disorder during pregnancy
• Risk of discontinuing maintenance psychotropic medications

Suppes T, et al. *Arch Gen Psychiatry*. 1991
Faedda GL, et al. *Arch Gen Psychiatry*. 1993
Primary aim: determine the risk of major malformations among infants exposed to atypical antipsychotics

Examined Medicaid claim data from 1,341,715 pregnancies

After adjustment for confounding, the risk ratio for congenital malformation in exposed versus unexposed infants was 1.05 (95% CI=0.96-1.16)

A slightly increased risk in overall and cardiac malformations was noted for risperidone
A NEW Research Study at the Massachusetts General Hospital Center for Women’s Mental Health

To determine the safety of atypical antipsychotics in pregnancy for women and their babies

Participation will involve 3 brief phone interviews over approximately 8 months

Call Toll-Free: 1-866-961-2388
Primary aim: determine the risk of major malformations among infants exposed to second-generation antipsychotics

Prospectively enrolled 487 women

The odds ratio for major malformations comparing exposed and unexposed infants was 1.25 (95% CI=0.13-12.19)

Current data indicate that second-generation antipsychotics are not major teratogens

Study is ongoing and continues to enroll women
JCP CME: ORIGINAL RESEARCH

Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics

Adele C. Viguera, MD, MPH\textsuperscript{a,b,c,*}; Marlene P. Freeman, MD\textsuperscript{a,b}; Lina Góez-Mogollón, MD, MSc\textsuperscript{a}; Alexandra Z. Sosinsky, MS\textsuperscript{d}; Sara A. McElheny, BA\textsuperscript{a}; Taylor R. Church, BS\textsuperscript{b}; Amanda V. Young, BA\textsuperscript{a}; Phoebe S. Caplin, BA\textsuperscript{a}; David Chitayat, MD\textsuperscript{a}; Sonia Hernández-Diaz, MPH, DrPH\textsuperscript{d}; and Lee S. Cohen, MD\textsuperscript{a,b}

Table 4. Unadjusted and Adjusted Odds Ratios for Risk of Major Malformations Comparing Exposure Status With Second-Generation Antipsychotics (N = 1,344 Infants)

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Prevalence of Malformations</th>
<th>Odds Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>First trimester exposure to SGAs (n = 640)</td>
<td>16</td>
<td>2.50%</td>
<td>Adjusted: 1.483</td>
<td>0.625–3.517</td>
</tr>
<tr>
<td>Unexposed to SGA (n = 704)</td>
<td>14</td>
<td>1.99%</td>
<td>Unadjusted: 1.264</td>
<td>0.612–2.610</td>
</tr>
</tbody>
</table>

Viguera et al 2021
Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics

Marlene P. Freeman\(^1,2\) • Adele C. Viguera\(^{1,2,3}\) • Lina Góez-Mogollón\(^1\) • Amanda V. Young\(^1\) • Phoebe S. Caplin\(^1\) • Sara A. McElheny\(^1\) • Taylor R. Church\(^1\) • David Chitayat\(^4\) • Sonia Hernández-Diaz\(^5\) • Lee S. Cohen\(^1,2\)

Received: 9 November 2020 / Accepted: 12 February 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021, corrected publication April 2021

Table 2  Odds ratio comparing number of malformations among infants exposed to aripiprazole \((N=163)\) versus comparison group \((N=704)\)

<table>
<thead>
<tr>
<th>Group</th>
<th>(N)</th>
<th>Prevalence</th>
<th>Odds ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st trimester exposure to aripiprazole ((N=163))</td>
<td>7</td>
<td>4.26%</td>
<td>Unadjusted: 2.212 adjusted 1.349</td>
<td>0.878, 5.571 0.433, 4.917</td>
</tr>
<tr>
<td>Unexposed to second-generation antipsychotic ((N=704))</td>
<td>14</td>
<td>1.99%</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 4 – Pooled risk ratio of major malformations in babies exposed to quetiapine

<table>
<thead>
<tr>
<th>Data Source</th>
<th>Risk Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Habermann 2013*</td>
<td>1.46 (0.57-3.75)</td>
</tr>
<tr>
<td>Sadowski 2013*</td>
<td>2.49 (0.64-9.71)</td>
</tr>
<tr>
<td>Huybrechts 2016#</td>
<td>1.01 (0.88-1.17)</td>
</tr>
<tr>
<td>Cohen 2018 (current report)#</td>
<td>0.90 (0.15-5.46)</td>
</tr>
<tr>
<td><strong>Pooled risk ratio</strong>**</td>
<td>1.03 (0.89-1.19)</td>
</tr>
<tr>
<td>P-value to assess homogeneity of the data</td>
<td>P=0.526</td>
</tr>
</tbody>
</table>

*healthy control group

#comparison group, adjusted for underlying psychiatric disorder

**accumulated evidence suggests no meaningful increased risk with a pooled null risk ratio.
Prevalence of ADHD and Autism Spectrum Disorders in Children with Prenatal Exposure to Antipsychotic Medications

By MGH Center for Women’s Mental Health | August 31st, 2021 | Psychiatric Disorders During Pregnancy | 0 Comments

We have seen an increasing number of women of reproductive age treated with the newer atypical antipsychotic agents, and more women seek consultations regarding the reproductive safety of these newer medications. Over the last couple of years, we have seen a series of studies assessing the reproductive safety of this class of medications. However, we have very little information on the long-term effects of prenatal exposure to antipsychotic medications.

From womensmentalhealth.org
Lithium Use in Pregnancy and the Risk of Cardiac Malformations

Elisabetta Patorno, M.D., Dr.P.H., Krista F. Huybrechts, Ph.D.,
Brian T. Bateman, M.D., Jacqueline M. Cohen, Ph.D., Rishi J. Desai, Ph.D.,
Helen Mogun, M.S., Lee S. Cohen, M.D.,
and Sonia Hernandez-Diaz, M.D., Dr.P.H.

https://womensmentalhealth.org/posts/12021/?doing_wp_cron=1506358912.7760159969329833984375
Lithium and Pregnancy

- Lithium Register of Babies 1970s
- Ebstein’s Anomaly: 0.05 – 0.1% risk
- Recent analysis from Medicaid database shows dose-dependent increase in risk of cardiovascular anomalies

<table>
<thead>
<tr>
<th>Exposure Group</th>
<th>No. of Pregnancies</th>
<th>No. of Events</th>
<th>Prevalence per 100 Births</th>
<th>Propensity-Score-Adjusted Risk Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No exposure</td>
<td>1,322,955</td>
<td>15,251</td>
<td>1.15</td>
<td>Reference</td>
</tr>
<tr>
<td>Exposure to lithium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤600 mg/day</td>
<td>305</td>
<td>&lt;11</td>
<td>1.64</td>
<td>1.11 (0.46–2.64)</td>
</tr>
<tr>
<td>601–900 mg/day</td>
<td>235</td>
<td>&lt;11</td>
<td>2.13</td>
<td>1.60 (0.67–3.80)</td>
</tr>
<tr>
<td>&gt;900 mg/day</td>
<td>123</td>
<td>&lt;11</td>
<td>4.88</td>
<td>3.22 (1.47–7.02)</td>
</tr>
<tr>
<td>Exposure to lamotrigine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤100 mg/day</td>
<td>904</td>
<td>&lt;11</td>
<td>1.11</td>
<td>0.70 (0.38–1.30)</td>
</tr>
<tr>
<td>101–200 mg/day</td>
<td>620</td>
<td>&lt;11</td>
<td>1.61</td>
<td>1.00 (0.54–1.86)</td>
</tr>
<tr>
<td>&gt;200 mg/day</td>
<td>421</td>
<td>&lt;11</td>
<td>1.66</td>
<td>1.02 (0.49–2.13)</td>
</tr>
</tbody>
</table>

**Figure 2.** Absolute and Relative Risk of Cardiac Malformations among Lithium-Exposed and Lamotrigine-Exposed Infants as Compared with Unexposed Infants, Stratified According to the Mother's Dose of the Drug.

Stratification was according to thirds of the first prescribed daily dose that was filled during the first trimester. A separate exposure propensity score was estimated in each dose stratum as the predicted probability of receiving the treatment-dose range of interest versus no treatment, conditional on the covariates reported in Tables S6 through S9 in the Supplementary Appendix. For each estimated propensity score, the population in the nonoverlapping areas of the propensity-score distributions was trimmed, and 50 strata were created on the basis of the distribution of the treated women. Weights for the reference group were calculated according to the distribution of the exposed women among propensity-score strata and were used to estimate adjusted risk ratios and 95% confidence intervals.
Valproic Acid and Pregnancy

- Overall risk of malformations elevated (6-10%): neural tube defects, cardiac anomalies, cleft lip/palate, limb abnormalities
- Dose dependent: Risk for major malformations highest (25.2%) in women on high dose valproate (above 1450 mg/day)
- Higher rates associated with polytherapy
- Neurodevelopmental sequelae: Increased risk of autism spectrum disorders, behavioral problems, lower IQ
- Folic acid appears to ameliorate risk of autism spectrum disorders but not risk of malformations
- UK and France have banned use of valproic acid in certain populations of reproductive age women
Other Antiepileptic Drugs and Pregnancy: North American AED Registry (2012)

- Of the 5,667 women taking an AED as monotherapy during the first trimester, 4,899 were eligible for analysis. The risks of major malformations were:
  - 9.3% (30 of 323) for valproate (Depakote)
  - 4.2% (15 of 359) for topiramate (Topamax)
  - 3.0% (31 of 1,033) for carbamazepine (Tegretol)
  - 2.4% (11 of 450) for levetiracetam (Keppra)
  - 2.2% (4 of 182) for oxcarbazepine (Trileptal)
  - 2.0% (31 of 1,562) for lamotrigine (Lamictal)

Growing data on safety of gabapentin (Patanooga, 2020, PLoS1)

Hernandez-Diaz et al, Neurology, 2012
Cognitive Function in 6 year olds Following Fetal Exposure to AED’s

Child IQ at 6 years, by exposure to maternal antiepileptic drug use and periconceptional folate


Mean (95% CIs) are shown for folate (solid lines) and no folate (dashed lines).
Essential Reads: Neurodevelopmental Outcomes in Children with Prenatal Exposure to Antiepileptic Drugs

By MGH Center for Women's Mental Health | September 1st, 2021 | Child Development, Child Outcomes | 0 Comments

While much data focuses on the risk of prenatal exposure to antiepileptic drugs (AEDs) and the risk of congenital malformations, there is a growing body of literature to indicate that exposure to certain antiepileptic drugs, most notably valproic acid (VPA, Depakote) during critical periods of development may be associated with long-lasting neurodevelopmental deficits across multiple domains. While
Treatment of Bipolar Illness During Pregnancy: What is a Reasonable Strategy?

- Lithium and lamotrigine have well characterized reproductive safety profiles, low absolute risks
- Lithium may be the best characterized and reasonable alternative for women who require an anti-manic agent but its use is declining
- Lamotrigine appears reasonable for the prevention of depressive episodes (but not for mania per se)
- Atypical antipsychotics have growing body of data and do not at this time appear to be major teratogens
  - May be reasonable to continue during pregnancy, particularly if patient has had good response, psychotic symptoms, is a lithium non-responder, or atypical was critical in affording euthymia
Benzodiazepines

- Methodological issues have confounded reports: dose, duration, class of BZD, other drug exposures, recall bias
- Risk of oral clefts following first trimester exposure (0-0.6%)
- Most studies show no increase in malformations, no consistent pattern of defects
- Incidence of neonatal adverse sequelae is low

Stimulants during Pregnancy

• From the current available data from prospective, retrospective and case control studies it can be concluded that none of the medications (except guanfacine, where data is unavailable) used for the treatment of ADHD is a major human teratogen.

• Available data do suggest the possibility that psychostimulants, especially amphetamines, may increase the risk of preeclampsia and possibly certain other adverse gestational outcomes; the absolute risk, however, is low.

• Long-term neurodevelopmental studies on the offspring are sparse

• If treatment is pursued, methylphenidate, amphetamine and bupropion appear to be better choices than other medication where reproductive safety data are sparse
Message from the Acting Associate Commissioner

Dear Women’s Health Colleagues,

Today, the Office of Women’s Health is sharing an important announcement issued by FDA regarding the use of cannabis and cannabis-derived products while pregnant or breastfeeding. There are many potential negative health effects from using marijuana and other products containing tetrahydrocannabinol (THC) during pregnancy and while breastfeeding. Therefore, FDA strongly advises against the use of cannabidiol (CBD), THC, and marijuana in any form during pregnancy or while breastfeeding. I encourage you to read the consumer update below.

Sincerely,

Kaveeta Vasisht, M.D., Pharm.D.
Acting Associate Commissioner for Women’s Health

What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding

Cannabis and Cannabis-derived products have become increasingly available in recent years, with new and different types of products appearing all the time. These products raise questions and concerns for many consumers. And if you are pregnant or breastfeeding, you might have even more questions about whether these products are safe for you.

FDA strongly advises against the use of cannabidiol (CBD), tetrahydrocannabinol (THC), and marijuana in any form during pregnancy or while breastfeeding.

Read the full Consumer Update
ECT During Pregnancy

- Treatment of choice when expeditious management is imperative
- Use in delusional depression, mania
- External fetal monitoring, ultrasonography
- Comprehensive treatment team
Essential Reads: Guidelines for the Use of Electroconvulsive Therapy During Pregnancy

By MGH Center for Women's Mental Health | August 4th, 2021 | Depression, Essential Reads, Psychiatric Disorders During Pregnancy | 0 Comments

Electroconvulsive therapy (ECT) is one of the most effective treatments for depression, with response rates consistently higher than those observed in clinical trials of traditional antidepressants. Furthermore, ECT may be more effective than medications for treatment-refractory depression. The American Psychiatric Association (APA) recommends ECT for patients who have not responded to pharmacological treatments, as well as for those patients who experience severe psychiatric symptoms, including psychosis, suicidal ideation, catatonia, and mania.
Treatment Guidelines for Psychotropic Drug Use in Pregnancy

LEE S. COHEN, M.D.
VICKI L. HELLER, M.D.
JERROLD F. ROSENBAUM, M.D.

Despite the apparent risks of psychotropic drug exposure in pregnancy, many pregnant women receive psychotropics. The major concerns associated with the use of antipsychotics, antidepressants, benzodiazepines, and lithium carbonate in pregnancy are reviewed, with clinical approaches for assessing the relative risks and benefits of treatment of psychiatrically ill pregnant patients and for choosing and instituting therapy with these agents.